DSM invests in purification technology company

Heerlen/The Netherlands – DSM Venturing, the corporate venturing unit of Royal DSM, has participated in an equity investment round in the Danish company Upfront Chromatography, the world’s leading developer of customized industrial protein chromatography processes. The downstream processing platform developed by Upfront is of great potential to contribute to all biotechnology-derived products from DSM. DSM Pharmaceutical Products is a global provider of custom manufacturing services to the pharmaceutical and biopharmaceutical industries with a broad menu of services in protein production and in clinical, commercial and fill and finish areas. The company’s achievements in biopharmaceutical production have resulted in a significant urgency to realize breakthroughs in downstream processing, enabling more efficient purification of monoclonal antibodies and other biopharmaceutical proteins. Leendert Staal, CEO of DSM Pharmaceutical Products, comments: “Upfront is at the forefront of technological breakthroughs in downstream processing. Through our investment we want to support further developments in the company which will benefit both DSM and Upfront.”